Quarterly report pursuant to Section 13 or 15(d)

Financial Instruments - Additional Information (Detail)

v3.23.3
Financial Instruments - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 01, 2022
Sep. 14, 2021
Jul. 31, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
Nov. 16, 2021
Schedule Of Available For Sale Securities [Line Items]                
Contingent consideration, current         $ 500,000 $ 500,000 $ 8,067,000  
Sale of stock price per share               $ 27.74
Impairment         0 0    
Other Assets | Level 2                
Schedule Of Available For Sale Securities [Line Items]                
Strategic investment         2,750,000 2,750,000 $ 2,750,000  
Investment at fair value         $ 2,021,000 $ 2,021,000    
Pandologic Ltd [Member]                
Schedule Of Available For Sale Securities [Line Items]                
Business acquisition, effective date of acquisition   Sep. 14, 2021            
Business acquisition, percentage of ownership interests acquired   100.00%            
Business acquisition, name of acquired entity   PandoLogic, Ltd. (“PandoLogic”)            
Business acquisition, date of acquisition agreement   Jul. 21, 2021            
March 2022 Acquisition [Member]                
Schedule Of Available For Sale Securities [Line Items]                
Business acquisition, effective date of acquisition Mar. 01, 2022              
Business acquisition, percentage of ownership interests acquired 100.00%              
Acquisition earnout amount     $ 3,500,000          
Contingent earnout $ 3,015,000              
Stock Consideration [Member] | PandoLogic Merger Agreement [Member]                
Schedule Of Available For Sale Securities [Line Items]                
Sale of stock price per share         $ 20.53 $ 20.53    
Minimum [Member]                
Schedule Of Available For Sale Securities [Line Items]                
Contingent earnout       $ 10,825,000        
Maximum [Member] | Pandologic Ltd [Member]                
Schedule Of Available For Sale Securities [Line Items]                
Contingent consideration, current   $ 65,000,000            
Maximum [Member] | March 2022 Acquisition [Member]                
Schedule Of Available For Sale Securities [Line Items]                
Acquisition earnout amount $ 4,500,000